Pharmacotherapy of comorbid mood, anxiety, and substance use disorders

Subst Use Misuse. 2005;40(13-14):2021-41, 2043-8. doi: 10.1080/10826080500294924.

Abstract

Mood and anxiety disorders commonly co-occur with substance use disorders. Exploration of the neurobiology of substance use disorders and mood and anxiety disorders have found that the neural circuitry in mood, anxiety, and substance use disorders is clearly overlapping. These discoveries have encouraged the exploration of a number of pharmacotherapeutic agents in the treatment of co-occurring mood, anxiety, and substance use disorders. In this article, recent data on the pharmacotherapeutic treatment of mood and anxiety disorders in individuals with substance use disorders are reviewed. Some of the barriers to the use of pharmacotherapy in individuals with substance use disorders are discussed.

Publication types

  • Review

MeSH terms

  • Anxiety Disorders / diagnosis
  • Anxiety Disorders / drug therapy*
  • Anxiety Disorders / epidemiology*
  • Bipolar Disorder / diagnosis
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / epidemiology
  • Comorbidity
  • Depression / diagnosis
  • Depression / drug therapy
  • Depression / epidemiology
  • Diagnosis, Differential
  • Humans
  • Mood Disorders / diagnosis
  • Mood Disorders / drug therapy*
  • Mood Disorders / epidemiology*
  • Obsessive-Compulsive Disorder / diagnosis
  • Obsessive-Compulsive Disorder / drug therapy
  • Obsessive-Compulsive Disorder / epidemiology
  • Panic Disorder / diagnosis
  • Panic Disorder / drug therapy
  • Panic Disorder / epidemiology
  • Phobic Disorders / diagnosis
  • Phobic Disorders / drug therapy
  • Phobic Disorders / epidemiology
  • Stress Disorders, Post-Traumatic / diagnosis
  • Stress Disorders, Post-Traumatic / drug therapy
  • Stress Disorders, Post-Traumatic / epidemiology
  • Substance-Related Disorders / epidemiology*
  • Substance-Related Disorders / rehabilitation*